Drug Database
PI

pitavastatin + valsartan (Livalsartan / Livasartan)

✓ Approved

JW Pharmaceutical · AGTR1 · 小分子

什么是 pitavastatin + valsartan?

pitavastatin + valsartan 是一种小分子,由JW Pharmaceutical研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名Livalsartan, Livasartan
公司JW Pharmaceutical
药物类别小分子
分子靶点AGTR1, HMGCR
给药途径Oral (PO)
状态Approved

作用机制

分子靶点

pitavastatin + valsartan 作用于 2 个分子靶点:

AGTR1angiotensin II receptor type 1 (HAT1R, AT1)
HMGCR3-hydroxy-3-methylglutaryl-CoA reductase (LDLCQ3, LGMDR28)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

pitavastatin + valsartan 针对 2 个适应症,涉及 2 个治疗领域。

治疗领域疾病/病症分期
Metabolism and nutrition disordersHypercholesterolaemia✓ Approved
Vascular disordersHypertension✓ Approved

相关研究文献

PubMedThe American journal of cardiology2026-11-18

Differential Reverse Remodeling but Preserved Clinical Benefit of Sacubitril/Valsartan in Ischemic vs Non‑Ischemic HFrEF.

Carluccio Erberto E, Dini Frank L FL, Correale Michele M, Dattilo Giuseppe G et al.

Sacubitril/valsartan is associated with left ventricular reverse remodeling (LVRR) and improved outcomes in heart failure with reduced ejection fraction (HFrEF). However, differences in LVRR between ischemic and non-ischemic HFrEF and its relationship with clinical outcomes remain unclear. In this multicenter, open‑label study, cardiac remodeling changes from baseline to 8-12 months after sacubitril/valsartan initiation were retrospectively compared between ischemic and non‑ischemic HFrEF patients. The outcome endpoint was a composite of all‑cause mortality/HF-rehospitalization. Among 608 patients enrolled, 302 (49.7%) had ischemic etiology. Baseline LVEF, end-diastolic volume index (LVEDVi) and end-systolic volume index (LVESVi) were similar between ischemic and non-ischemic groups. Both groups showed significant improvement at follow-up in LV volumes and LVEF (P<0.001 for all). However, adjusted mixed-effects models showed smaller LVEF gains (2.44% vs 4.51%, interaction P<0.0001) and smaller LVESVI reductions (-4.68 mL/m2 vs -7.43 mL/m2, interaction P<0.0001) in ischemic patients, while LVEDVi changes did not differ between the two groups (interaction P=0.263). Over a median follow-up of 63 months (IQR 32-77), 249 patients reached the composite endpoint. In multivariable analysis, LVRR was associated with the endpoint independent of etiology. In an exploratory analysis, LVRR accounted statistically for approximately 9% (95% CI 1.40-26.1%; p=0.0164) of the modeled pre-to-post association with outcome. Significant LVRR after sacubitril/valsartan was observed in both ischemic and non-ischemic HFrEF, although the magnitude of improvement was smaller in ischemic disease. LVRR was associated with more favorable outcomes regardless of etiology, but only a modest proportion of the modeled pre-to-post association with outcome was statistically attributable to LVRR.

PMID 43051350
阅读全文 →
PubMedJournal of molecular histology2026-11-18

Efficacy of sacubitril/valsartan and bosentan in amelioration of estradiol induced endometrial changes via regulation of Wnt/β-catenin and IL6/JAK/STAT3 pathways.

Refaie Marwa Monier Mahmoud MMM, Ibrahim Manar Fouli Gaber MFG, Sherkawy Hoda S HS, Mohamed Hala Mansour Mohamed HMM et al.

Endometrial hyperplasia (EHP) commonly affects elderly females in the pre-menopausal period and can progress to carcinoma. Immune dysregulation has a crucial role in mediating such disorders. Thus, studying its pathogenesis and finding ameliorative medical treatment becomes mandatory. This motivated us to perform the current experiment of induced EHP in female rats using estradiol (EST) (2 mg/kg/day) intramuscular injection with or without using bosentan (BOS) (50 mg/kg/day) and/or Sacubitril/valsartan (SV) (60 mg/kg/day) for 3 weeks. We found typical histopathological features of EHP, elevation of total oxidant status (TOS), oxidative stress index (OSI), interleukin 6/Janus kinase/Signal transducer and activator of transcription 3 (IL6/JAK/STAT3), and Wnt/β-catenin pathways with increased uterine weights. However, there is a significant diminution in total antioxidant capacity (TAC) and caspase-3 immune expression. Interestingly, BOS and/or SV administration significantly ameliorated the histopathological and biochemical disturbances. This improvement may be attributed to the pharmacological ability of SV to block angiotensin receptors and neprilysin besides blocking endothelin receptors by BOS. Furthermore, SV/BOS could regulate apoptosis with antioxidant and anti-inflammatory properties.

PMID 43049843
阅读全文 →
PubMedMolecular pharmacology2026-11-17

Temporal effects of acute kidney injury on hepatic function, drug elimination, and transcriptomics in a mouse ischemic reperfusion injury model.

Holt Kimberly K, Chung Seung-Wook SW, Pham Ly L, Camacho Raul C RC et al.

While the effect of acute kidney injury on the kidney and the elimination of renally cleared drugs is well understood, the impact on liver clearance is less characterized. Therefore, using the mouse kidney ischemia-reperfusion injury (IRI) acute kidney injury model, we examined the pharmacokinetics (PK) of 2 hepatically cleared drugs, pitavastatin and antipyrine, pre-IRI and post-IRI, as well as changes in gene expression in liver and kidney, and the impact on kidney and liver injury markers. Post-IRI, the glomerular filtration rate was reduced by 99% at 2 hours and improved mildly by 72 hours (82% reduction in glomerular filtration rate). Additionally, post-IRI, kidney and liver damage biomarkers increased, as well as the uremic toxin, indoxyl sulfate, all of which were restored partially on day 16 post-IRI. The terminal exposure of pitavastatin and antipyrine was increased when dosed 2 and 24 hours post-IRI, compared with when dosed to control mice. The change in pitavastatin exposure could be explained by decreased clearance, but for antipyrine, the effect was complex and likely multifactorial. Altered expression of drug metabolizing enzymes and transporter genes in the liver was observed post-IRI. In addition, increased mRNA expression of genes involved in various pathways such as tryptophan metabolism were observed from day 1 to 16 post-IRI. Changes in the kynurenine pathway possibly contributed to changes in drug elimination because of changes in energy status. Overall, this study supports renohepatic crosstalk post-IRI that impacts hepatic clearance mechanisms. SIGNIFICANCE STATEMENT: The elimination of the hepatically cleared drugs, pitavastatin and antipyrine, decreased rapidly after ischemic injury in a mouse ischemia-reperfusion acute kidney injury model, indicating crosstalk between the kidney and liver after acute kidney injury. Long-lasting changes in mRNA levels of transporters and enzymes were observed in hepatic tissues, but it is unlikely that these explained the acute decrease in elimination of test drugs. Changes in the kynurenine pathway, involved in energy generation, could possibly contribute to acute effects on hepatic drug elimination.

PMID 43044418
阅读全文 →
PubMedTherapeutic advances in musculoskeletal disease2026-11-16

Pitavastatin use and risk of osteoporosis and osteoporotic fractures: A nationwide retrospective cohort study.

Chang Chao-Ming CM, Wu Wen-Tung WT, Tsai Chun-Teng CT, Chang Chih-Hui CH et al.

Osteoporosis and dyslipidemia share overlapping pathophysiological mechanisms, and statins have been suggested to exert pleiotropic effects on bone metabolism. However, the comparative skeletal impact of individual statins, particularly pitavastatin, remains insufficiently characterized. To investigate the association between pitavastatin use and the risk of incident osteoporosis and osteoporotic fractures compared with other statins. Retrospective propensity score-matched cohort study (1:4 matching ratio). Using Taiwan's National Health Insurance Research Database, we identified patients aged 50-80 years with newly prescribed pitavastatin or other statins between 2014 and 2021. Individuals with prior osteoporosis or osteoporotic fractures were excluded. Propensity score matching was performed to adjust for age, sex, comorbidities, and co-medications. The primary outcome was a composite of newly diagnosed osteoporosis or osteoporotic fracture (hip, spine, or humeral/wrist), identified by ICD-9/10 codes. Adjusted hazard ratios (aHRs) were estimated using multivariable Cox proportional hazard regression models, several sensitivity analyses were conducted. Among 9,940 pitavastatin users and 39,760 matched other statin users, pitavastatin use was associated with a potentially lower risk of the composite outcome (aHR 0.72; 95% CI, 0.63-0.82). For subtype of composite outcome: osteoporosis (aHR 0.78; 95% CI, 0.63-0.97), hip fracture (aHR 0.64; 95% CI, 0.43-0.96), spine fracture (aHR 0.56; 95% CI, 0.41-0.76), and humeral/wrist fracture (aHR 0.79; 95% CI, 0.63-0.99). Risk reduction was observed across sex and age strata, most pronounced in patients aged 61-70 years (aHR 0.63; 95% CI, 0.51-0.79). Results remained consistent across multiple sensitivity analyses. pitavastatin use was associated with a potentially lower risk of incident osteoporosis and osteoporotic fractures compared with other statins. The observational design precludes causal inference, and outcomes were ascertained through administrative codes without bone mineral density confirmation. These hypothesis-generating findings warrant confirmation in prospective studies incorporating direct bone health assessments.

PMID 43036377
阅读全文 →
PubMedCardiology clinics2026-11-16

The Role of Medical Therapy in Hypertrophic Cardiomyopathy: An Updated Review.

Lee Jung-Won JW, Chun Kyeong-Hyeon KH, Choi Eui-Young EY, Seo Jiwon J

This review highlights recent advances in hypertrophic cardiomyopathy (HCM) treatment, focusing on how to effectively implement both traditional and novel pharmacologic strategies in clinical practice. Traditional medications like beta-blockers and calcium channel blockers continue to play a critical role. However, new treatments, such as cardiac myosin inhibitors, provide an innovative approach for relieving symptoms, especially in obstructive HCM cases. Emerging therapies, including sodium-glucose cotransporter 2 inhibitors, sacubitril/valsartan, and ninerafaxstat, show promising benefits. Proper management of related conditions such as atrial fibrillation and heart failure is also essential. A comprehensive approach that considers individual patient characteristics and the specific subtype of HCM is essential for achieving optimal outcomes.

PMID 43039637
阅读全文 →
PubMedEuropean journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences2026-11-15

Development of a non-targeted fingerprint profiling LC-HRMS method combined with chemometric analysis as a new approach for the detection of unexpected impurities.

Schneider Mandy M, Meins Jürgen J, Sandner Viktor V, Schubert-Zsilavecz Manfred M et al.

Valsartan drugs were recalled in 2018 because of the coincidental discovery of unexpected N-nitrosodimethylamine (NDMA). The fact that NDMA was not detected by the established comprehensive quality control methods is mainly due to the targeted approach applied being devoted to the determination of known and expected impurities. This study examines the use of a non-targeted screening approach to monitor the fingerprint profiles of finished products for unexpected impurities. To this end, we developed a profiling method for ramipril tablets using LC-HRMS coupled with SIMCA (soft independent modelling of class analogies) chemometric analysis. Fingerprint profiles were generated using a pentafluorophenyl reversed phase column with a methanol/water gradient coupled to a qTOF mass spectrometer with electrospray ionization in positive and negative mode. By applying chemometric analysis to the untargeted fingerprint profiles, it was possible to distinguish the fingerprint profiles generated from "clean" and spiked ramipril batches at impurity concentrations as low as 10 µg/L demonstrating the methods suitability for trace-level impurity profiling. SIMCA even allowed the identification of the substances responsible for the deviations in the fingerprint profiles. This study shows that untargeted fingerprint profiling coupled with multivariate data analysis is capable of being applied in addition to existing targeted quality control methods as a proactive approach to detect unexpected impurities instead of reactive batch recalls.

PMID 43033898
阅读全文 →

注册免费账户还可查看另外 7474 篇文献

免费注册查看全部文献 →

了解更多pitavastatin + valsartan